First Quarter Results Presentation
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Mesoblast
- DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
- COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
- MSB Wins Fierce Biotech Innovation Award for Remestemcel-L
- DSMB Recommends Continuation of Phase 3 COVID-19 Trial
- ODAC Votes in Favor of Remestemcel-L for GvHD
Later from Mesoblast
- Novartis and Mesoblast Remestemcel-L Collaboration
- Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
- Mesoblast Phase 3 Chronic Heart Failure Results
- Trading halt
- Mesoblast Update on COVID-19 ARDS Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast